Multimer Detection System-Oligomerized Amyloid Beta (MDS-OA β): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia

Jacqueline Cotoong Dominguez; Jeryl Ritzi Tan Yu; Ma Fe De Guzman; Encarnita Ampil; Anne Cristine Guevarra; Ma Lourdes Joson; Macario Reandelar Jr; Ma Socorro Martinez; Antonio Ligsay; Ferron Ocampo; SangYun Kim

doi:10.1155/2022/9960832

Multimer Detection System-Oligomerized Amyloid Beta (MDS-OA β): A Plasma-Based Biomarker Differentiates Alzheimer's Disease from Other Etiologies of Dementia

Int J Alzheimers Dis. 2022 May 2:2022:9960832. doi: 10.1155/2022/9960832. eCollection 2022.

Authors

Jacqueline Cotoong Dominguez^{1

2

3}, Jeryl Ritzi Tan Yu¹, Ma Fe De Guzman^{2

4}, Encarnita Ampil^{1

2

5}, Anne Cristine Guevarra², Ma Lourdes Joson^{1

2

5}, Macario Reandelar Jr^{2

4

6

7

8}, Ma Socorro Martinez^{1

3}, Antonio Ligsay^{3

9}, Ferron Ocampo², SangYun Kim¹⁰

Affiliations

¹ St Luke's Medical Center, Institute for Neurosciences, Philippines.
² Institute for Dementia Care Asia, Philippines.
³ St. Luke's College of Medicine William H. Quasha Memorial, Philippines.
⁴ Research and Biotechnology Division, St. Luke's Medical Center, Philippines.
⁵ Department of Neuroscience and Behavioral Medicine, Faculty of Medicine and Surgery, University of Santo Tomas, Philippines.
⁶ Far Eastern University, Dr. Nicanor Reyes Medical Foundation, Philippines.
⁷ Our Lady of Fatima University, Philippines.
⁸ New Era University College of Medicine, Philippines.
⁹ College of Science and the Graduate School, University of Santo Tomas, Philippines.
¹⁰ Department of Neurology, Seoul National University College of Medicine & Neurocognitive Behavior Center, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.

Abstract

With emerging amyloid therapies, documentation of the patient's amyloid status to confirm the etiology of a clinical diagnosis is warranted prior to instituting amyloid-based therapy. The Multimer Detection System-Oligomeric Amyloid-β (MDS-OAβ) is a noninvasive blood-based biomarker utilized to measure Aβ oligomerization tendency. We determined the difference in MDS-OAβ ratio across the groups: (a) no cognitive impairment or subjective cognitive impairment (NCI/SCI), (b) Alzheimer's disease (AD), (c) non-AD, and (d) mixed Alzheimer's disease-Vascular dementia (AD-VaD). MDS-OAβ level was not significantly different between AD and mixed AD-VaD, but both groups were significantly different from the NCI/SCI and from the non-AD group. An MDS-OAβ level of >1 could potentially indicate clinical variants of AD or mixed pathology (AD-VaD).